Targeting tomorrow: Evaluation of novel agents for infants with KMT2A-rearranged acute lymphoblastic leukaemia.

IF 7.2 2区医学 Q1 HEMATOLOGY

Blood Reviews Pub Date : 2026-09-22 DOI:10.1016/j.blre.2026.101435

Taylor A Ferguson, Stephen C C Dymock, Sung K Chiu, Laurence C Cheung, Rishi S Kotecha

{"title":"Targeting tomorrow: Evaluation of novel agents for infants with KMT2A-rearranged acute lymphoblastic leukaemia.","authors":"Taylor A Ferguson, Stephen C C Dymock, Sung K Chiu, Laurence C Cheung, Rishi S Kotecha","doi":"10.1016/j.blre.2026.101435","DOIUrl":null,"url":null,"abstract":"<p><p>Infants with KMT2A-rearranged (KMT2A-r) acute lymphoblastic leukaemia (ALL) have a historically poor prognosis with high rates of relapse. Further treatment intensification with conventional chemotherapy is precluded by dose-limiting toxicities. Extensive preclinical evaluation has been performed to identify novel therapies to improve outcome for infants with KMT2A-r ALL. However, there is considerable heterogeneity regarding the extent of experimental research conducted and combined with the increasing volume of preclinical studies, presents a barrier to selecting the best agents for translation into clinical trials. In addition, the relative rarity of infant ALL limits the number of novel therapies that can be clinically evaluated at any one time. In this systematic review, we detail the preclinical studies of novel agents performed for KMT2A-r infant ALL and highlight areas for further investigation, providing the basis to enhance future preclinical research and integrate novel agents into clinical practice to improve outcomes for infants with KMT2A-r ALL.</p>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":" ","pages":"101435"},"PeriodicalIF":7.2000,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.blre.2026.101435","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Infants with KMT2A-rearranged (KMT2A-r) acute lymphoblastic leukaemia (ALL) have a historically poor prognosis with high rates of relapse. Further treatment intensification with conventional chemotherapy is precluded by dose-limiting toxicities. Extensive preclinical evaluation has been performed to identify novel therapies to improve outcome for infants with KMT2A-r ALL. However, there is considerable heterogeneity regarding the extent of experimental research conducted and combined with the increasing volume of preclinical studies, presents a barrier to selecting the best agents for translation into clinical trials. In addition, the relative rarity of infant ALL limits the number of novel therapies that can be clinically evaluated at any one time. In this systematic review, we detail the preclinical studies of novel agents performed for KMT2A-r infant ALL and highlight areas for further investigation, providing the basis to enhance future preclinical research and integrate novel agents into clinical practice to improve outcomes for infants with KMT2A-r ALL.

查看原文本刊更多论文

靶向明天：kmt2a重排急性淋巴细胞白血病婴儿新药物的评价。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Reviews 医学-血液学

CiteScore

13.80

自引率

1.40%

发文量

期刊介绍： Blood Reviews, a highly regarded international journal, serves as a vital information hub, offering comprehensive evaluations of clinical practices and research insights from esteemed experts. Specially commissioned, peer-reviewed articles authored by leading researchers and practitioners ensure extensive global coverage across all sub-specialties of hematology.